We are live on ! Find out more
IGC icon

IGC Pharma

35 hedge funds and large institutions have $1.14M invested in IGC Pharma in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

17% more funds holding

Funds holding: 3035 (+5)

0.82% less ownership

Funds ownership: 5.2%4.39% (-0.82%)

16% less capital invested

Capital invested by funds: $1.36M → $1.14M (-$220K)

Holders
35
Holders Change
+5
Holders Change %
+16.67%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
6
Reduced
5
Closed
4
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change

IGC Hedge Fund Activity: Q1 2026 in Review

35 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2026, worth a combined $1.14M — down 16% from $1.36M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new IGC positions and 4 closed out — a net gain of 7 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $50.8K. The largest seller was Renaissance Technologies, cutting an estimated $121K.

  • 35 institutional investors held IGC Pharma (IGC) as of Q1 2026, up from 30 in Q4 2025.
  • Funds reported $1.14M of IGC Pharma stock for Q1 2026, down 16% quarter-over-quarter.
  • 11 funds opened new IGC Pharma positions in Q1 2026 and 4 closed out, a net change of +7 holders.
  • The largest IGC Pharma buyer in Q1 2026 was Geode Capital Management, an estimated $50.8K added.
  • The largest IGC Pharma seller in Q1 2026 was Renaissance Technologies, an estimated $121K sold.

Based on aggregated 13F filings for Q1 2026.